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might be the use of a single methodol-
ogy for the study of a single factor ver-
sus several analyses evaluating multiple 
determinants of drug activity.
Because only few studies addressed 
this point, we appreciated the article by 
Mairinger et al.1 evaluating by means 
of both immunohistochemistry and 
quantitative polymerase chain reaction 
(qPCR), the expression of five folate 
pathway genes in 63 MPMs. This study 
suggested an association between high 
reduced folate carrier and low folylpo-
lyglutamate synthetase (FPGS) mRNA 
expression with overall survival, but 
not for thymidylate synthase (TS). 
However, no significant association 
was observed with objective response.
Conversely, we reported a cor-
relation of both TS mRNA and protein 
expression with overall survival in 99 
MPM patients who were given carbo-
platin + pemetrexed.2 Moreover, higher 
levels of TS were associated with a 
minor probability of disease control and 
progression-free survival. Similarly, 60 
patients with low TS protein expres-
sion benefited from pemetrexed + cis-
platin, but no correlation was found for 
mRNA levels.3 However, a recent study 
indicated a lack of correlation for both 
TS and FPGS protein expression in 85 
patients receiving pemetrexed as pri-
mary therapy.4
These discrepancies might be 
because of differential methods, treat-
ment heterogeneity, and relatively 
small or heterogeneous sample size. 
Because FPGS is essential for peme-
trexed polyglutamylation, which pro-
longs its intracellular retention, one 
would have expected that a low FPGS 
would be related to a poor survival. 
Mairinger et al.1 used a polyclonal 
anti-FPGS that was not tested in FPGS-
overexpressing or -deficient cells, and 
evaluated patients treated in first- and 
second-line with different regimens. 
Although qPCR is also a specific 
technique for the analysis of archived 
paraffin-embedded tissues, mRNA can 
differ from protein expression. This 
holds particularly true for FPGS, which 
undergoes extensive mRNA splicing, 
leading to multiple different RNA frag-
ments, and various truncated protein 
fragments or no protein.5 Splicing is an 
ubiquitous phenomenon, which might 
explain the counterintuitive association 
of low FPGS with longer survival and 
the lack of a relationship between FPGS 
protein and mRNA. Therefore, spliced 
variants should be tested in the valida-
tion of FPGS antibodies. Last but not 
least, future studies should evaluate the 
active drug metabolites, such as intra-
cellular pemetrexed polyglutamates, to 
obtain a complete picture of pharmaco-
kinetics or pharmacodynamics effects.
Another critical point consists of 
the evaluation of tumor heterogeneity 
and possible evolution of cancer cells 
after tumor relapse, which should be 
documented with multiple sampling of 
the single tumor and repeated biopsies.
In conclusion, we agree that 
observational studies can provide a 
strong rationale for future trials, but we 
believe that interlaboratory validation 
of techniques for sample collection or 
analysis, especially qPCR or immuno-
histochemistry, is essential. Moreover, 
larger and uniformly treated popula-
tions, according to powered statistical 
analysis and integration with functional 
data, are essential to validate the best 
markers for personalized treatment of 
MPM patients.
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In Response:
We appreciate the critical com-
ments to our article1 on predictors of 
pemetrexed response in malignant 
mesotheliomas by Zucali et al.2
The authors contrasted our find-
ing by their published study,2 where 
they found a correlation between low 
thymidylate synthase (TS) as evalu-
ated by immunohistochemistry (IHC) 
and mRNA, and better overall survival 
and longer progression-free survival 
in 99 malignant pleural mesothelioma 
(MPM) patients given carboplatin and 
pemetrexed treatment. In contrast to 
what they discussed in the letter, they 
personally investigated only TS and 
excition repair cross complementation 
group 1 (ERCC1). Their findings are 
not surprising, because several studies 
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reported either a correlation between 
TS levels and therapeutic response to 
pemetrexed, or none at all.3–7
One of the problems of previous 
studies is that in some studies expe-
rienced pathologists investigated the 
immunostained sections, whereas in 
other studies no pathologist has ever 
evaluated the immunohistochemically 
stained tissue sections. Because evalu-
ation of immunohistochemical sections 
is done semiquantitatively for staining 
intensity and percentage of tumor cells, 
an investigator should be trained in 
this field and know the pitfalls. Studies 
where inexperienced researchers evalu-
ate the sections should raise caution on 
the validity of the results.
We agree with the authors that 
finding predictive markers for peme-
trexed response in malignant meso-
theliomas requires an investigation of 
the whole thymidylate pathway, which 
we tried as best as we could. We also 
agree with Giovanetti that a multi-
institutional prospective trial is prob-
ably needed to identify the mechanisms 
that are responsible for the pemetrexed 
action in some but not all patients.
With our investigation, we were 
the first to investigate the thymidylate 
pathway in a more complex way, in con-
trast to previous investigations, includ-
ing the cited one, which focused only on 
one or two molecules, instead of follow-
ing the way of thymidylate from uptake 
to metabolism to action in the tumor.
We are aware that mRNA lev-
els can differ from protein expression, 
especially in those enzymes, which 
undergo extensive mRNA splicing.
“Therefore, spliced variants 
should be tested in the validation of 
FPGS antibodies.”
We are not aware of those many 
antibodies directed toward FPGS, and 
we could not identify validated anti-
bodies directed against splice variants, 
which will work on formalin-fixed par-
affin-embedded tissues. Therefore, we 
chose polyclonal antibodies, which will 
pick up at least some splice variants, 
and thus, minimize the risk of being too 
specific and detecting only one variant. 
Of note is the fact that, only two dif-
ferent physiological splice variants are 
known until now.
In contrast to the statement of 
Zucali et al.,2 for this study both IHC 
and quantitative polymerase chain reac-
tion were accurately validated using 
several tests. Validation of IHC was 
done on both whole-tissue sections and 
sections of tissue microarrays. Normal 
lung tissue was included as negative 
control, and squamous cell carcinomas 
of the lung, with known overexpression 
of TS and FPGS, were used as posi-
tive controls. Quantitative polymerase 
chain reaction analyses were performed 
according to the minimum information 
for publication of quantitative real-time 
PCR experiments (MIQE)8 guidelines, 
which is the current standard pro-
cedure, to overcome the problem of 
interlaboratory variances. According 
to these recommendations, two refer-
ence genes for normalization purposes 
and positive controls and the necessary 
nontemplate controls were included. 
All purchased assays were developed 
and established by Applied Biosciences 
(Foster City, CA). To overcome the 
problem of mRNA degradation in for-
malin-fixed paraffin-embedded tumor 
specimens, small amplicon sizes (75 
bp–100 bp) were used for the analyses 
of mRNA levels. To ensure measuring 
of only mRNA, all assays were per-
formed using span exon–exon borders.
Even if FPGS is a protein with 
differentially spliced isoforms having 
differing properties, the assessment of 
total FPGS protein levels might be an 
appropriate biomarker for predicting 
response or resistance to pemetrexed-
based chemotherapy in MPM. The use 
of a polyclonal antibody, like the one 
with which we applied IHC, is known to 
detect several FPGS isoforms. In addi-
tion, our assay on demand covers both 
the physiologically known isoforms 
NM_001018078.1 and NM_004957.4.
Last but not least, “future studies 
should evaluate the active drug metabo-
lites, such as intracellular pemetrexed-
polyglutamates, to obtain a complete 
picture on pharmacokinetics/pharmaco-
dynamics effects.” We totally agree with 
this statement, but in addition, would 
recommend including also uptake mech-
anisms, which are equally important.9
The authors also discussed tumor 
heterogeneity and recommended mul-
tiple sampling of the single tumor and 
repeated biopsies. It seems the authors 
are not very familiar with clinical prac-
tice: In those patients, who undergo 
resection (either pleuropneumonectomy 
or decortication) there is ample tissue 
available, however, in many patients 
diagnosed at late stages, surgical inter-
vention is restricted to small biopsies 
for diagnosis, which is the basis for 
further therapeutic strategy. Rebiopsy is 
not a very common practice, especially, 
when requested for only scientific pur-
pose. No ethics committee would agree 
to such a request.
In our case, we also produced 
a tissue microarray with at least three 
different cores from each tumor to 
overcome the problem of a possible het-
erogeneity within the tumor.
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